Share This On:
CNN – The results of recent trials that tested much-anticipated Alzheimer’s disease drugs dashed the hopes of patients with the debilitating condition. The most recent disappointment came from the large trial for solanezumab, by Eli Lilly, announced last month.
But experts across the field say hope is not lost. They believe we will have some form of drug against the disease by 2025, albeit most likely a pilot version that will need to be upgraded.
This target, in less than a decade, is a goal agreed upon by world leaders at the G8 dementia summit in 2013.
Researchers believe there are enough competitors in the race to get at least a few to the finish line on time.
“There are still a number of late-stage trials in progress,” said Heather Snyder, senior director of medical and scientific operations at the Alzheimer’s Association.
“2025 is a realistic target in terms of where we are with the science. … We’re not off-track at this point in time.”
More Health Stories
- OECS Ministers of Health Meeting December 10, 2019
- Disruption of services at Canaries Wellness Centre December 9, 2019
- Cellma training at OKEU December 9, 2019
- Funding for OECS Regional Health Project December 4, 2019
- Legislation governing employment at new hospital discussed December 4, 2019
- Update on reopening and closure of wellness centres December 3, 2019
- World AIDS Day community outreach activities December 3, 2019
- Message from the President of NCPD December 3, 2019